Table 7 Current ongoing early phase I/II trials with BRAF/MEK inhibitors
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
BRAF/MEK inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
ABM-1310 | BRAF inhibitor (BRAF V600E) | NCT04190628 (1) | Monotherapy | Advanced BRAFV600 E mutated solid tumor including NSCLC |
LXH254 | BRAF and CRAF inhibitor | NCT02974725 (1) | Combination with LTT462, Trametinib, Ribociclib | Advanced BRAF or KRAS mutant NSCLC |
Trametinib | MEK inhibitor | NCT03225664 (1/2) | Combination with Pembrolizumab | Advanced NSCLC with EGFR or ALK mutation with progression on first line therapy |